PubMed Health⌕ Search

Biomedical subjects

H Duffin

Publications and source records attributed to H Duffin.

6 recordsLinked to original sources
PubMed1988

Locally advanced adenocarcinoma of the breast without distant metastasis treated with multimodal therapies.

Locally advanced breast cancer has been treated with a variety of primary treatments with or without adjuvant therapies. This study combines radiation, chemotherapy, and surgery as a multimodal program for Stage III breast cancer. Radiation was started on day 1: 4600 rad were administered to the breast and 4500 rad were administered to the axilla and supraclavicular areas. Chemotherapy was started on day 1 with weekly intravenous injections of 5-fluorouracil (5FU) (300 mg/m2), methotrexate (15 mg/m2), vincristine (0.625 mg/m2), oral cytoxan (60 mg/m2), and prednisone (30 mg/m2 for two weeks, then 20 mg/m2 for two weeks, then 10 mg/m2 for two weeks). The 5FU, methotrexate, and cytoxan were given for 10 months postsurgery. This combination of modalities produced a complete remission in all 13 patients with Stage III breast cancer after two months of therapy. The median disease-free period was two years. The median survival was 44 months. This approach to the management of Stage III breast cancer is worthy of further investigation.

Adenocarcinoma↗
PubMed1987

A profile of disordered micturition in the elderly at home.

A prevalence survey of disturbed micturition in the elderly identified 7% with important degrees of disorder, 1% with lesser disorder and 1% who were catheterized. Incontinence, urgency, frequency and nocturia were the symptoms most commonly reported. Fifty-three per cent of people describing incontinence used preventive aids but one third of these continued to experience wetting of external clothing. Crude categorization of dysfunction on the basis of symptoms suggested that a component of unstable bladder was present in approximately 4% of the elderly population.

Aged↗
PubMed1986

Provision of services for incontinent elderly people at home.

Results of a survey of elderly people living at home suggest that 8% suffer from important degrees of urinary dysfunction and are accessible to community based services. Supply of NHS incontinence aids was inadequate, and improvements in provision are recommended. Attendance at a continence clinic established for the survey period suggests a need for additional specialist services to be made available close to home. Correspondence between actual and predicted cystometric diagnosis provides encouragement to develop simple, valid assessment procedures as an aid to patient management. For the average District Health Authority serving a population of 250 000, two continence nurse advisers and 50 continence clinic sessions per annum are recommended for people aged 75 and over.

Aged↗
PubMed1985

Hepatic arterial and systemic chemotherapy for the treatment of primary and secondary malignancies of the liver.

Twenty-two patients with metastatic and primary cancer of the liver were treated with 5-fluoro-2'-deoxyuridine (5FUDR), Mitomycin C (Mito C), and 1 (-2-chlorethyl)-4(methyl-cyclohexyl)-1-nitrosourea (MeCCNU). 5FUDR 0.3 mg/kg/day was administered as a continuous infusion via the hepatic artery. Mito C (10 mg/M2) and MeCCNU (50 mg/M2) were given I.V. and orally, respectively, every 8 weeks. Remission of the neoplastic lesions within the liver was seen in 10 patients (4CR, 6PR). Five patients had stabilization of their lesion neoplasm for at least 4 months. The response rate in this study was 6/15 (40%) in patients with colon cancer metastatic to the liver. Toxicity was mainly hematologic and hepatic. Three patients experienced a platelet count below 25,000 and/or white blood count below 1000. Fifteen patients had hepatic toxicity showing elevation in SGOT and SGPT. The SGOT and SGPT returned to normal when the 5FUDR was discontinued. The combination of 5FUDR intraarterially, and Mito C and MeCCNU systemically, demonstrated activity in malignancies of the liver. This study proved that chemotherapy can be administered systemically and regionally with acceptable toxicity.

Administration, Oral↗
PubMed1982

VP-16 and adriamycin in patients with advanced breast cancer.

Twenty-eight patients with advanced adenocarcinoma of the breast were treated with a combination of VP-16 and adriamycin (VAD). Two complete (CR), and eight partial (PR) remissions were observed. The CR plus PR produced a 36% response rate in this study. Nine additional patients had stable disease for at least 2 months. No drug deaths were seen with this combination, but thrombocytopenia, leukopenia, and vomiting were observed. Alopecia was seen in 100% of the patients treated with the above combination. This study suggests that the combination of adriamycin and VP-16 may be a good second-line therapy for patients with adenocarcinoma of the breast who failed and/or relapsed to CMFVP.

Adenocarcinoma↗